Pyrrolidine dithiocarbamate protects against scopolamine-induced cognitive impairment in rats
详细信息 查看全文
- 作者：Mai A. Abd-El-Fattah ; Noha F. Abdelakader ; Hala F. Zaki
- 关键词：Dementia ; Pyrrolidine dithiocarbamate ; Acetylcholineesterase ; Oxidative stress ; Neuroinflammation ; Heat shock protein 70
- 刊名：European Journal of Pharmacology
- 出版年：15 January, 2014
- 年：2014
- 卷：723
- 期：Complete
- 页码：330-338
- 全文大小：2567 K
文摘
Alzheimer's disease (AD) is a chronic neurodegenerative disorder that leads to disturbances of cognitive functions. Although the primary cause of AD remains unclear, brain acetylcholine deficiency, oxidative stress and neuroinflammation may be considered the principal pathogenic factors. The present study was constructed to investigate the anti-amnestic effect of pyrrolidine dithiocarbamate (PDTC) on scopolamine-induced behavioral, neurochemical and biochemical changes in rats. PDTC (50 and 100 mg/kg) and donepezil (2.5 mg/kg) were orally administered for 14 successive days. Dementia was induced at the end of the treatment period by a single injection of scopolamine (20 mg/kg; i.p.), and Y-maze test was conducted 30 min thereafter. Rats were then sacrificed and homogenates of cortical and hippocampal tissues were used for the estimation of noradrenaline, dopamine, serotonin and heat shock protein 70 contents along with acetylcholinesterase activity. In addition, certain oxidative stress markers, pro-inflammatory and anti-inflammatory cytokines were assessed. Histological examination of cortical and hippocampal tissues was also performed. Scopolamine resulted in memory impairment that was coupled by alterations in the estimated neurotransmitters, heat shock protein 70, acetylcholinesterase activity, oxidative stress as well as inflammatory biomarkers. Histological analysis revealed serious damaging effects of scopolamine on the structure of cerebral cortex and hippocampus. Pretreatment of rats with PDTC in both doses mitigated scopolamine-induced behavioral, biochemical, neurochemical and histological changes in a manner comparable to donepezil. The observed anti-amnestic effect of PDTC makes it a promising candidate for clinical trials in patients with cognitive impairment.